Hopefully, the current confirmation of a VIP role in cholera patients may reawaken interest in such studies, including testing newer highly potent and mucosally active compounds to determine if they can safely interrupt the diarrheagenic process and shorten disease duration more than what is possible with antibiotics and fluid replacement alone. This evidence concerns the gene VIP and vibrio infectious disease.